HPV testing 2
Thursday, June 16, 2016
Oral Communications
•
OC 08
•
2:15 PM
>
4:00 PM
•
HPV testing 2
•
Mozart 4-5
Oral Communications
•
OC 08-01
•
The revolution in cervical cancer detection from conventional cytology to real-time molecular detection
See abstract
>
A.
Ali
Rabaan
•
OC 08-02
•
Performance of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology. Results of the Pipavir study
See abstract
>
T.
Thoeodoros
Agorastos
•
OC 08-03
•
First round of co-testing in the area of hospital De Barbastro (Spain)
See abstract
>
R.
Rosa
Oncins
•
OC 08-04
•
Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand
See abstract
>
W.
Wichai
Termrungruanglert
•
OC 08-05
•
Contribution of screening cytology to the diagnosis of invasive cervical cancer in the context of cotesting every 3 years
See abstract
>
W.
Walter
Kinney
•
OC 08-06
•
High-risk human papillomavirus prevalence by age after randomized implementation of HPV-test in primary screening
See abstract
>
A.
Ameli
Tropé
•
OC 08-07
•
Human papillomavirus testing versus liquid-based cytology for non-attendees of cervical cancer screening: results of a randomized controlled trial
See abstract
>
M.
Manuela
Viviano
•
OC 08-08
•
Evaluation of cervical cancer (CxCa) screening strategies (co-test, HPV, PAP) using the CRMM
See abstract
>
C.
Catherine
Popadiuk
•
OC 08-09
•
When can cervical cancer be eradicated? A model for projecting cervical cancer incidence and mortality from 2016 to 2040
See abstract
>
C.
C.R.
Cohen
•
OC 08-10
•
Staging Pre-Cervical Cancer Using Combined E6, E7 mRNA Quantification and Cell Cycle Analysis (OncoTect 3Dx)
See abstract
>
P.
Petros
Karakitsos
•
OC 08-11
•
HPV E7 oncoprotein-based Elisa assay for triage of HPV-positively screened women
See abstract
>
A.
Andreas
Kaufmann
|